The road to resistance: EGFR mutation and cetuximab

Alberto Bardelli; Pasi A. Jänne

doi:10.1038/nm.2646

The road to resistance: EGFR mutation and cetuximab

Alberto Bardelli, Pasi A. Jänne

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

Original language	English
Pages (from-to)	199-200
Number of pages	2
Journal	Nature Medicine
Volume	18
Issue number	2
DOIs	https://doi.org/10.1038/nm.2646
Publication status	Published - Feb 2012

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

Access to Document

10.1038/nm.2646

Cite this

@article{6d592c4155a4416daeef01c80dd96bac,

title = "The road to resistance: EGFR mutation and cetuximab",

abstract = "Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).",

author = "Alberto Bardelli and J{\"a}nne, {Pasi A.}",

year = "2012",

month = feb,

doi = "10.1038/nm.2646",

language = "English",

volume = "18",

pages = "199--200",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - The road to resistance

T2 - EGFR mutation and cetuximab

AU - Bardelli, Alberto

AU - Jänne, Pasi A.

PY - 2012/2

Y1 - 2012/2

N2 - Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

AB - Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

UR - http://www.scopus.com/inward/record.url?scp=84856721608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856721608&partnerID=8YFLogxK

U2 - 10.1038/nm.2646

DO - 10.1038/nm.2646

M3 - Article

C2 - 22310681

AN - SCOPUS:84856721608

SN - 1078-8956

VL - 18

SP - 199

EP - 200

JO - Nature Medicine

JF - Nature Medicine

IS - 2

ER -

The road to resistance: EGFR mutation and cetuximab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this